Cancer Biology & Medicine

Papers
(The TQCC of Cancer Biology & Medicine is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030116
Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants91
Current cancer burden in China: epidemiology, etiology, and prevention91
Stimuli-responsive nanocarriers for therapeutic applications in cancer44
Predictive value of MGMT promoter methylation on the survival of TMZ treated <i>IDH</i>-mutant glioblastoma39
Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies35
Recent progress of nanotechnology-based theranostic systems in cancer treatments30
Tumorigenic bacteria in colorectal cancer: mechanisms and treatments29
Advances in lung cancer screening and early detection28
The advanced development of molecular targeted therapy for hepatocellular carcinoma27
Breast cancer screening and early diagnosis in Chinese women27
Competing endogenous RNAs in lung cancer27
Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA26
Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas25
Exosome-mediated cellular crosstalk within the tumor microenvironment upon irradiation25
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification25
Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer25
Global pattern and trends of colorectal cancer survival: a systematic review of population-based registration data24
The role and its mechanism of intermittent fasting in tumors: friend or foe?23
Methods for monitoring cancer cell pyroptosis23
Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development23
Strategies to enhance monoclonal antibody uptake and distribution in solid tumors23
Nanotechnology assisted photo- and sonodynamic therapy for overcoming drug resistance23
Major roles of the circadian clock in cancer23
Circular RNAs: new biomarkers of chemoresistance in cancer22
Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer22
The IL-33/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization21
Gold-based nanomaterials for the treatment of brain cancer21
Personalized immunotherapy in cancer precision medicine21
Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity21
Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies20
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases20
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells19
VEGFR2 inhibition hampers breast cancer cell proliferation <i>via</i> enhanced mitochondrial biogenesis19
Morphine-3-glucuronide upregulates PD-L1 expression <i>via</i> TLR4 and promotes the immune escape of non-small cell lung cancer19
Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas18
Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy18
Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion18
BYSL contributes to tumor growth by cooperating with the mTORC2 complex in gliomas18
Bacterial outer membrane vesicle-based cancer nanovaccines18
NEDD9 promotes cancer stemness by recruiting myeloidderived suppressor cells <i>via</i> CXCL8 in esophageal squamous cell carcinoma17
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events16
Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial16
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study16
Biological roles and potential clinical values of circular RNAs in gastrointestinal malignancies16
Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives16
Targeting myeloid-derived suppressor cells for cancer therapy15
Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies15
Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer14
Targeting PP2A for cancer therapeutic modulation14
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer <i>in vivo</i>14
Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials13
Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids13
N6-methyladenosine (m6A) RNA modification in tumor immunity13
L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma13
Living biobank-based cancer organoids: prospects and challenges in cancer research13
Immunology and immunotherapy in breast cancer13
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer13
LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA13
Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study12
Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling12
Exosomal miR-155 from gastric cancer induces cancer-associated cachexia by suppressing adipogenesis and promoting brown adipose differentiation via C/EPBβ12
Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma11
A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cance11
Prospective study of the effect of ERAS on postoperative recovery and complications in patients with gastric cancer11
The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma11
Anti-tumor pharmacology of natural products targeting mitosis11
PGK1-coupled HSP90 stabilizes GSK3β expression to regulate the stemness of breast cancer stem cells11
The m6A writers regulated by the IL-6/STAT3 inflammatory pathway facilitate cancer cell stemness in cholangiocarcinoma10
CD13 inhibition augments DR4-induced tumor cell death in a p-ERK1/2-independent manner10
Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment10
Updating targets for natural killer/T-cell lymphoma immunotherapy10
The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms10
A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer9
Circular RNAs: implications of signaling pathways and bioinformatics in human cancer9
SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer9
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation9
The biogenesis, function and clinical significance of circular RNAs in breast cancer8
LncRNA DPP10-AS1 promotes malignant processes through epigenetically activating its cognate gene DPP10 and predicts poor prognosis in lung cancer patients8
Analysis of the <i>HNF4A</i> isoform-regulated transcriptome identifies CCL15 as a downstream target in gastric carcinogenesis8
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP8
Modulating microRNAs in cancer: Next-generation therapies8
The advance of adjuvant treatment for triple-negative breast cancer8
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up8
The cancer-testis gene, <i>MEIOB</i>, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency8
Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas8
Cancer immunology and immunotherapy8
Akt isoforms differentially provide for chemoresistance in prostate cancer7
Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA7
Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy7
Tumor organoids for cancer research and personalized medicine7
A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma7
Effects of population aging on the mortality burden of related cancers in urban and rural areas of China, 2004–2017: a population-based study7
Epithelial-mesenchymal transition-related circular RNAs in lung carcinoma7
SNORA23 inhibits HCC tumorigenesis by impairing the 2'-O-ribose methylation level of 28S rRNA7
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi7
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma7
Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations7
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer7
Research progress in hepatitis B virus covalently closed circular DNA7
Early detection of gastric cancer in China: progress and opportunities7
0.050838947296143